FindMyKOL

Charles Kuzma, MD

Basic profile

Southeast Clinical Oncology Research Consortium

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPinehurst, NC · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Charles Kuzma is an Oncology physician affiliated with Southeast Clinical Oncology Research Consortium. OpenAlex indexes 37 publications with 4,049 citations (h-index 17).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
37publications

Publications indexed by OpenAlex. Counts exclude supporting files.

4,049citations

Citations across these publications.

17h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
52companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

52 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Amgen
    Program year20258 paymentsResearch
    $289,595
  • Pfizer
    Program year202520 paymentsResearch
    $274,143
  • Mirati Therapeutics
    Program year20252 paymentsResearch
    $36,196
All 142 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    55.3%
    Aromatase Inhibitor17.8%
    Letrozole66%Anastrozole34%
    Part D≥35 patients
    Thalidomide Analog14.9%
    Revlimid63%Lenalidomide29%Pomalyst9%
    Part D<11 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    15.5%
    Serotonin-3 Receptor Antagonist7.3%
    Ondansetron Hcl72%Ondansetron Odt28%
    Part D<11 patients
    Potassium supplement3.1%
    Potassium Chloride100%
    Part D≥11 patients

    + 3 more classes in this area

  • Nervous system

    11%
    Gabapentinoids5.6%
    Gabapentin100%
    Part D≥11 patients
    Phenothiazine3.9%
    Prochlorperazine Maleate100%
    Part D≥29 patients

    + 1 more class in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”